Daiichi Sankyo’s PharmaForce To Invest $145 Million to Expand Sterile Manufacturing Operations
By

By
PharmaForce, a Columbus, Ohio-based sterile drug product development and manufacturing company, will invest $145 million to expand two of its existing facilities in the area of Columbus, Ohio. The announcement…

Wasdell Invests in Packaging Facility
By

By
Wasdell, a Newcastle, UK-headquartered packaging company, plans to build a pharmaceutical packaging facility in Dundalk, Ireland. Wasdell says the facility will provide offer quality-control import testing, a variety of current…

Catalent in ADC Pact
By

By
Catalent Pharma Solutions and Vaccinex, a Rochester, New York-headquartered clinical-stage biotechnology company, have signed an agreement to develop an antibody-drug conjugate (ADC). The companies plan to use Catalent’s proprietary SMARTag…

Mustang Bio in CAR-T Therapy Pact
By

By
Mustang Bio, a New York-headquartered clinical-stage biopharmaceutical company and a subsidiary of the biopharmaceutical company, Fortress Biotech, has signed a license agreement with Harvard University and a research collaboration agreement…

Russian Biopharm Company Biocad To Manufacture Biosimilars for North African Market
By

By
Biocad, a St. Petersburg, Russia-headquartered biotechnology company, has announced that it will begin manufacturing biosimilars of rituximab and bevacizumab in Morocco for the North African market in partnership with Sothema…

Metrics Contract Services Appoints Associate Director of Pharmaceutical Development
By

By
Metrics Contract Services, the Greenville, North Carolina-based contract pharmaceutical development and manufacturing division of Mayne Pharma, has appointed Yogesh D. Sadhale, PhD, as associate director of pharmaceutical development. Sadhale will…

Bluebird bio Acquires Mfg Facility for Gene, Cell Therapies
By

By
Bluebird bio, a Cambridge, Massachusetts-based clinical-stage gene therapy company, has acquired a 125,000-square-foot manufacturing facility in Durham, North Carolina. Once construction and validation is complete, the site will produce lentiviral…

Lonza in Gene-Therapy Pact
By

By
Lonza, Massachusetts Eye and Ear (MEE), a specialty hospital in Boston, Massachusetts, and Akouos, a Boston-based biotechnology company, have signed license agreements for exclusive rights to Lonza and MEE’s ancestral…

Private Equity Firm Acquires Majority Interest in LGM Pharma
By

By
LGM Pharma, an active pharmaceutical ingredient (API) supplier, has received a majority equity investment from New Harbor Capital, a Chicago, Illinois-based private equity firm. LGM Pharma is involved in the…

FDA Issues Draft Guidance on Drug Supply Chain Security Act
By

By
The US Food and Drug Administration (FDA) has issued draft guidance, Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier, to further detail certain provisions from…